 | • レポートコード：B-MOR-08480 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・製薬 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、前立腺がん診断および治療の世界市場について調べ、前立腺がん診断および治療の世界規模、市場動向、市場環境、種類別（前立腺肥大、前立腺腺がん、小細胞がん、その他）分析、診断別（組織生検、直腸指診、臨床検査、画像診断）分析、治療別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・前立腺がん診断および治療の世界市場インサイト ・前立腺がん診断および治療の世界市場環境 ・前立腺がん診断および治療の世界市場動向 ・前立腺がん診断および治療の世界市場規模 ・前立腺がん診断および治療の世界市場規模：種類別（前立腺肥大、前立腺腺がん、小細胞がん、その他） ・前立腺がん診断および治療の世界市場規模：診断別（組織生検、直腸指診、臨床検査、画像診断） ・前立腺がん診断および治療の世界市場規模：治療別 ・前立腺がん診断および治療の世界市場：地域別市場規模・分析 ・前立腺がん診断および治療の北米市場規模・予測 ・前立腺がん診断および治療のアメリカ市場規模・予測 ・前立腺がん診断および治療のヨーロッパ市場規模・予測 ・前立腺がん診断および治療のアジア市場規模・予測 ・前立腺がん診断および治療の日本市場規模・予測 ・前立腺がん診断および治療の中国市場規模・予測 ・前立腺がん診断および治療のインド市場規模・予測 ・前立腺がん診断および治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The prostate cancer diagnostics market is expected to witness a CAGR of 6.1% during the forecast period (2018-2023). North America was leading the global market with the largest revenue share in 2016.
High Prevalence Rate of Prostate Cancer
The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.
The other factors include innovation in drugs and developments in genomics and proteomics, rise in the funding in both public and private sectors, in the field of drug development, technological advancement in oncology diagnostics and therapeutics area.
Increasing Cost of the Prostate Cancer Drugs
There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low. Hence, only few people are capable of affording these drugs. Therefore, because of this high cost, the use of generic drugs is more, and hence, it is hindering the growth of the prostate cancer drugs market.
The other factors include, low success rate of clinical trials and side effects of the treatments.
The United States Dominates the Market
North America is the leading global market with the largest revenue share in 2016. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.
Key Developments in the Market
• February 2017: AstraZeneca entered into an agreement with TerSera Therapeutics LLC, for Zoladex in the United States and Canada. Zoladex is an injectable luteinising hormone-releasing agonist, which is used to treat prostate cancer, breast cancer, and certain benign gynaecological disorders.
Major Players: ABBOTT, ASTRAZENECA, ASTELLAS PHARMA INC., BAYER AG, BIOMARK DIAGNOSTICS INC., SANOFI, IPSEN, TOLMAR PHARMACEUTICALS INC., INDEVUS PHARMACEUTICALS INC., DENDREON INC., FERRING BV, AND CELLANYX LLC amongst others.
Reasons to Purchase this Report
• Current and future market outlook for prostate cancer diagnostics, in the developed and emerging markets
• Analyze various perspectives on the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High Disease Prevalence Rate of Prostate Cancer
6.1.2 Innovation in Drugs and Developments in Genomics and Proteomics
6.1.3 Rise in the Funding in Both Public and Private Sector in the Field of Drug Development
6.1.4 Technological Advancement in Oncology Diagnostics & Therapeutics Area
6.2 Market Restraints
6.2.1 High Cost Associated with Diagnostic Tests
6.2.2 Low Success Rate of Clinical Trials
6.2.3 Side Effects of Treatments
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Benign Prostatic Hyperplasia
7.1.2 Prostatic Adenocarcinoma
7.1.3 Small Cell Carcinoma
7.1.4 Others
7.2 By Diagnosis
7.2.1 Tissue Biopsy
7.2.2 Digital Rectal Examination
7.2.2.1 Transrectal Ultrasound
7.2.2.2 Transrectal Ultrasonography
7.2.3 Clinical Laboratory Examination
7.2.3.1 Prostate-Specific Antigen Testing
7.2.3.2 Urine Testing
7.2.3.3 Blood Testing
7.2.4 Diagnostic Imaging
7.3 By Treatment
7.3.1 Chemotherapy
7.3.2 Brachytherapy
7.3.3 Radiation therapy
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 AstraZeneca
9.3 Astellas Pharma Inc
9.4 Bayer AG
9.5 BioMark Diagnostics Inc.
9.6 Sanofi
9.7 Ipsen
9.8 TOLMAR Pharmaceuticals, Inc.
9.9 Indevus Pharmaceuticals Inc.
9.10 Dendreon Inc.
9.10 List Not Exhaustive
10. Future of the Market